Abstract
FosB is a member of the AP-1 family of transcription factors which represent important regulators of cell proliferation and differentiation. Based on prior results which indicated a role of FosB in breast cancer, we studied FosB protein and mRNA expression by immunohistochemistry and, partly, in situ hybridization in 68 mammary carcinomas and normal breast tissues. We found strong nuclear FosB immunoreactivity in epithelial cells of normal lobules and ducts, whereas carcinomas frequently showed loss of FosB expression (n = 8) or weak immunostaining (n = 24). Reduced FosB protein expression in tumors correlated with high grading (p = 0.005), negative estrogen and progesterone receptor status (p < 0.001), and strong HER2/neu expression (p = 0.025). Comparison with expression of seven cell-cycle regulators revealed an association of low/absent FosB staining with p16MTS1 overexpression (p = 0.005). RT-PCR showed expression of full-length FosB and the smaller splice variant FosB2 in most carcinomas and cell lines with and without FosB protein expression, indicating that both proteins are differentially regulated mainly at a post-transcriptional level. By sequence analysis of the coding region in four cell lines and 17 carcinomas we detected a mutation in HBL-100 cells. Our results indicate that high FosB expression might be necessary for normal proliferation and differentiation of mammary epithelial cells, and reduced FosB protein levels might be involved in dedifferentiation during breast tumorigenesis.
Similar content being viewed by others
References
Angel P, Karin M: The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072: 129-157, 1991
Karin M, Liu Z-G, Zandi E: AP-1 function and regulation. Curr Opin Cell Biol 9: 240-246, 1997
Ransone LJ, Visvader J, Lamph WW, Sassone-Corsi P, Verma IM: Fos and Jun interaction: the role of the leucine zipper. Int J Cancer 4: 10-21, 1989
Shaulian E, Karin M: AP-1 in cell proliferation and survival. Oncogene 20: 2390-2400, 2001
Van Dam H, Castellazzi M: Distinct roles of Jun:Fos and Jun:ATF dimers in oncogenesis. Oncogene 20: 2453-2464, 2001
Ransone LJ, Verma IM: Nuclear proto-oncogenes Fos and Jun. Ann Rev Cell Biol 6: 539-557, 1990
Lee W, Mitchell P, Tjian R: Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell 49: 741-752, 1987
Ryseck R-P, Bravo R: c-Jun, JunB, and JunD differ in their binding affinities to AP-1 and CRE consensus sequences: effect of Fos proteins. Oncogene 6: 533-542, 1991
Finzer P, Soto U, Delius H, Patzelt A, Coy JF, Poustka A, zur Hausen H, Rösl F: Differential transcriptional regulation of the monocyte chemoattractant protein-1 (MCP-1) gene in tumorigenic and non-tumorigenic HPV18 positive cells: the role of chromatin structure and AP-1 composition. Oncogene 19: 3235-3244, 2000
Krosl J, Sauvageau G: AP-1 complex is effector of Hoxinduced cellular proliferation and transformation. Oncogene 19: 5134-5141, 2000
Mechta F, Lallemand D, Pfarr CM, Yaniv M: Transformation by ras modifies AP-1 composition and activity. Oncogene 14: 837-847, 1997
Pospelova TV, Medvedev AV, Kukushkin AN, Svetlikova SB, van der Eb AJ, Dorsman JC, Pospelov VA: E1A+cHa-ras transformed rat embryo fibroblast cells are characterized by high and constitutive DNA binding activities of AP-1 dimers with significantly altered composition. Gene Expr 8: 19-32, 1999
Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJ: c-Jun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 18: 6063-6070, 1999
Soto U, Denk C, Finzer P, Hutter KJ, zur Hausen H, Rösl F: Genetic complementation to non-tumorigenicity in cervicalcarcinoma cells correlates with alterations in AP-1 composition. Int J Cancer 86: 811-817, 2000
Vallone D, Battista S, Pierantoni GM, Fedele M, Casalino L, Santoro M, Viglietto G, Fusco A, Verde P: Neoplastic transformation of rat thyroid cells requires the JunB and Fra-1 gene induction which is dependent on the HMGI-C gene product. EMBO J 16: 5310-5321, 1997
Chung JY, Huang C, Meng X, Dong Z, Yang CS: Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras transformed cells: structure-activity relationship and mechanisms involved. Cancer Res 59: 4610-4617, 1999
Darne C, Martinez A, Lallemand D, Morel L, Jean C, Saru JP, Schmid HP, Manin M: Down-regulation of AP-1 activities after polarization of vas deferens epithelial cells correlates with androgen-induced gene expression. J Steroid Biochem Mol Biol 72: 103-113, 2000
Ng DC, Shafaee S, Lee D, Bikle DD: Requirement of an AP-1 site in the calcium response region of the involucrin promoter. J Biol Chem 275: 24080-24088, 2000
Zerial M, Toschi L, Ryseck R-P, Schuermann M, Müller R, Bravo R: The product of a novel growth factor activated gene, FosB, interacts with Jun proteins enhancing their DNA binding activity. EMBO J 8: 805-813, 1989
Mumberg D, Lucibello FC, Schuermann M, Müller R: Alternative splicing of FosB transcripts results in differentially expressed mRNAs encoding functionally antagonistic proteins. Gene Dev 5: 1212-1223, 1991
Metz R, Kouzarides T, Bravo R: A C-terminal domain in FosB, absent in FosB/SF and Fra-1, which is able to interact with the TATA binding protein, is required for altered cell growth. EMBO J 13: 3832-3842, 1994
Angel P, Szabowski A, Schorpp-Kistner M: Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene 20: 2413-2423, 2001
Welter JF, Eckert RL: Differential expression of the Fos and Jun family members c-Fos, FosB, Fra-1, Fra-2, c-Jun, JunB and JunD during human epidermal keratinocyte differentiation. Oncogene 11: 2681-2687, 1995
Brown JR, Ye H, Bronson RT, Dikkes P, Greenberg ME: A defect in nurturing in mice lacking the immediate early gene FosB. Cell 86: 297-309, 1996
Gruda MC, van Amsterdam J, Rizzo CA, Durham SK, Lira S, Bravo R: Expression of FosB during mouse development: normal development of FosB knockout mice. Oncogene 12: 2177-2185, 1996
Jochum W, Passegué E, Wagner EF: AP-1 in mouse development and tumorigenesis. Oncogene 20: 2401-2412, 2001
Bamberger A-M, Methner C, Lisboa BW, Städtler C, Schulte HM, Löning T, Milde-Langosch K: Expression pattern of the AP-1 family in breast cancer: association of FosB expression with a well-differentiated, receptor-positive phenotype. Int J Cancer 84: 553-558, 1999
Milde-Langosch K, Bamberger AM, Methner C, Rieck G, Löning T: Expression of cell cycle regulatory proteins Rb, p16/MTS1, p27/Kip1, p21/Waf1, cyclin D1 and cyclin E in breast cancer: correlations with expression of activating protein-1 family members. Int J Cancer 87: 468-472, 2000
Milde-Langosch K, Bamberger A-M, Rieck G, Kelp B, Löning T: Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat 67: 61-70, 2001
Milde-Langosch K, Riethdorf S, Kraus-Pöppinghaus A, Riethdorf L, Löning T: Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas. Virchows Arch 439: 55-61, 2001
Remmele W, Stegner H-E: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140, 1987
Milde-Langosch K, Goemann C, Methner C, Rieck G, Bamberger AM, Löning T: Expression of Rb2/p130 in breast and endometrial cancer: correlations with steroid hormone receptor status and Rb expression. Br J Cancer 85: 552-556, 2001
Riethdorf L, Riethdorf S, Gützlaff K, Prall F, Löning T: Differential expression of the monocyte chemoattractant protein-1 in human papillomavirus-16-infected squamous intraepithelial lesions and squamous cell carcinomas of the cervix uteri. Am J Pathol 149: 1469-1475, 1996
Schlott T, Reimer S, Jahns A, Ohlenbusch A, Ruschenburg I, Nagel H, Droese M: Point mutations and nucleotide insertions in the mdm2 zinc finger structure of human tumours. J Pathol 182: 54-61, 1997
Dublin EA, Patel NK, Gillett CE, Smith P, Peters G, Barnes DM: Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histological parameters. Int J Cancer 79: 71-75, 1998
Emig R, Magener A, Ehemann V, Meyer A, Stilgenbauer F, Volkmann M, Wallwiener D, Sinn H-P: Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. Br J Cancer 78: 1661-1668, 1998
Passegue E, Wagner EF: JunB suppresses cell proliferation by transcriptional activation of p16 (INK4a) expression. EMBO J 19: 2969-2979, 2000
Rinehart-Kim J, Johnston M, Birrer M, Bos T: Alterations in the gene expression profile of MCF-7 breast tumor cells in response to c-Jun. Int J Cancer 88: 180-190, 2000
Heximer SP, Cristillo AD, Russell L, Forsdyke DR: Sequence analysis and expression in cultured lymphocytes of the human FOSB gene (GOS3). DNA Cell Biol 15: 1025-1038, 1996
Carillo S, Pariat M, Steff A-M, Roux P, Etienne-Julan M, Lorca T, Piechaczyk M: Differential sensitivity of Fos and Jun family members to calpains. Oncogene 9: 1679-1689, 1994
Salvat C, Aquaviva C, Jariel-Encontre I, Ferrara P, Pariat M, Stef AM, Carillo S, Piechaczyk M: Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 protein degradation in vivo? Mol Biol Rep 26: 45-51, 1999
Lucibello FC, Slater EP, Jooss KU, Beato M, Müller R: Mutual transrepression of Fos and the glucocorticoid receptor: involvement of a functional domain in Fos which is absent in FosB. EMBO J 9: 2827-2834, 1990
Rosen JM, Zahnow C, Kazansky A, Raught B: Composite response elements mediate hormonal and developmental regulation of milk protein gene expression. Biochem Soc Symp 63: 101-113, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Milde-Langosch, K., Kappes, H., Riethdorf, S. et al. FosB is Highly Expressed in Normal Mammary Epithelia, but Down-Regulated in Poorly Differentiated Breast Carcinomas. Breast Cancer Res Treat 77, 265–275 (2003). https://doi.org/10.1023/A:1021887100216
Issue Date:
DOI: https://doi.org/10.1023/A:1021887100216